JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.

JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
复制标题

DOI:
10.1007/s00277-020-04004-7
复制
发表时间:
2020-05
影响因子:
3.5
通讯作者:
Balasubramanian P
Balasubramanian P
中科院分区:
医学3区
文献类型:
--
作者:
Maddali M;Kulkarni UP;Ravindra N;Jajodia E;Arunachalam AK;Suresh H;Venkatraman A;George B;Mathews V;Balasubramanian P

文献摘要

参考文献

被引文献

相似文献

世界卫生组织2016年指南将JAK2突变(V617F或外显子12)的分子检测列为真性红细胞增多症(PV)的主要诊断标准。JAK2外显子12突变见于约2-5%的jak2v617f阴性PV病例。JAK2突变引起JAK-STAT通路的组成性激活,从而导致表型变化。JAK2外显子12突变的PV患者以红细胞增多为特征性表现。关于骨髓增生性肿瘤(mpn)中JAK2外显子12突变谱的报道有限。在这里,我们描述了一系列JAK2外显子12突变的MPN患者的特征,其中两个是与红细胞增多症相关的新变体。有趣的是,我们注意到两名表现为骨髓纤维化的患者有JAK2外显子12突变。
Molecular detection of JAK2 mutation (V617F or exon 12) is included as a major diagnostic criterion for polycythemia vera (PV) by the WHO 2016 guidelines. JAK2 exon 12 mutations are seen in about 2–5% of JAK2V617F-negative cases of PV. Mutations in JAK2 cause constitutive activation of JAK-STAT pathway which results in variable phenotypes. PV patients with exon 12 mutations in JAK2 present characteristically with erythrocytosis. There are limited reports describing the spectrum of JAK2 exon12 mutations in myeloproliferative neoplasms (MPNs). Here, we describe the characteristics of a series of MPN patients with mutations in exon 12 of JAK2 of which two were novel variants associated with polycythemia. Interestingly, we noted two patients presenting as myelofibrosis having JAK2 exon 12 mutations.
DOI: 10.1056/nejmoa065202
发表时间: 2007-02-01
期刊: The New England journal of medicine
影响因子: --
作者:
Scott LM;Tong W;Levine RL;Scott MA;Beer PA;Stratton MR;Futreal PA;Erber WN;McMullin MF;Harrison CN;Warren AJ;Gilliland DG;Lodish HF;Green AR
通讯作者: Green AR
DOI: 10.1200/jco.2012.42.3863
发表时间: 2012-11-20
影响因子: 45.3
作者:
Emanuel, Robyn M.;Dueck, Amylou C.;Mesa, Ruben A.
通讯作者: Mesa, Ruben A.
DOI: 10.1056/nejmoa1311347
发表时间: 2013-12-19
影响因子: 158.5
作者:
Klampfl, Thorsten;Gisslinger, Heinz;Kralovics, Robert
通讯作者: Kralovics, Robert
DOI: 10.1136/jclinpath-2016-203649
发表时间: 2016-08-01
影响因子: 3.4
作者:
Park, Chang-Hun;Lee, Ki-O;Kim, Hee-Jin
通讯作者: Kim, Hee-Jin
DOI: 10.1016/j.jmoldx.2013.07.006
发表时间: 2013-11-01
影响因子: 4.1
作者:
Furtado, Larissa V.;Weigelin, Helmut C.;Betz, Bryan L.
通讯作者: Betz, Bryan L.